Alpha Teknova, Inc. (TKNO) stock
TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30124% above fair value
$7.88+0.23 (+3.01%)
Close on Nov 18, 2026Market cap $423.06MP/E –Yield –
Alpha Teknova free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Alpha Teknova's free cash flow for the twelve months ending Jun 30, 2026 was -$7.35M. For fiscal 2025 it was -$9.79M. The highest annual figure on record is -$2.96M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.79M | – |
| FY2024 | Dec 31, 2024 | -$13.52M | – |
| FY2023 | Dec 31, 2023 | -$26.75M | – |
| FY2022 | Dec 31, 2022 | -$55.55M | – |
| FY2021 | Dec 31, 2021 | -$28.95M | – |
| FY2020 | Dec 31, 2020 | -$2.96M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$596.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$810.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.50M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.12M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.49M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.74M | -1264.3% |
| Q2 FY2021 | Jun 30, 2021 | -$8.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.06M | – |
| Q3 FY2020 | Sep 30, 2020 | $751.00K | – |
See a number that looks wrong?